Pancreatic Cancer Research

ResearcherJinan UniversityActive in the last 2 years

Lizhi Niu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-8808-0978; OpenAlex author ID A5027144599. Sources: OpenAlex.

Their work

Papers
24 (first author 4, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
35
Papers, trials and grants by year

2012: 5 papers · 2013: 5 papers · 2014: none · 2015: none · 2016: none · 2017: 5 papers · 2018: 2 papers · 2019: none · 2020: 3 papers · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper

Papers 24

  1. Guidelines for permanent iodine-125 seed interstitial brachytherapy for pancreatic cancer (2023 edition): The Chinese expert consensus workshop report. Co-author DOI 10.4103/jcrt.jcrt_2368_23↗
  2. Irreversible electroporation combined with chemotherapy and PD-1/PD-L1 blockade enhanced antitumor immunity for locally advanced pancreatic cancer. Last author DOI 10.3389/fimmu.2023.1193040↗
  3. Simultaneous Gemcitabine and Percutaneous CT-Guided Irreversible Electroporation for Locally Advanced Pancreatic Cancer. Last author DOI 10.1155/2022/3523769↗
  4. Chinese expert consensus of image-guided irreversible electroporation for pancreatic cancer. Co-author DOI 10.4103/jcrt.jcrt_1663_20↗
  5. Irreversible electroporation plus allogenic Vγ9Vδ2 T cells enhances antitumor effect for locally advanced pancreatic cancer patients. Co-author DOI 10.1038/s41392-020-00260-1↗
  6. Irreversible electroporation for liver metastasis from pancreatic cancer: A case report. Last author DOI 10.12998/wjcc.v8.i2.390↗
  7. Gemcitabine plus concurrent irreversible electroporation vs gemcitabine alone for locally advanced pancreatic cancer. Last author DOI 10.12998/wjcc.v8.i22.5564↗
  8. Using circulating tumor cells to evaluate the efficacy of irreversible electroporation for unresectasble pancreatic cancer. Co-author DOI 10.1007/s12026-017-8959-2↗
  9. Circulating Tumor DNA as a Sensitive Marker in Patients Undergoing Irreversible Electroporation for Pancreatic Cancer. Last author DOI 10.1159/000490874↗
  10. Percutaneous irreversible electroporation combined with allogeneic natural killer cell immunotherapy for patients with unresectable (stage III/IV) pancreatic c… Co-author DOI 10.1007/s00432-017-2513-4↗
  11. Short-term clinical efficacy of percutaneous irreversible electroporation combined with allogeneic natural killer cell for treating metastatic pancreatic cance… Co-author DOI 10.1016/j.imlet.2017.03.018↗
  12. Percutaneous Irreversible Electroporation for Ablation of Locally Advanced Pancreatic Cancer: Experience From a Chinese Institution. Last author DOI 10.1097/mpa.0000000000000703↗
  13. Clinical Practice Guidelines for Cryosurgery of Pancreatic Cancer: A Consensus Statement From the China Cooperative Group of Cryosurgery on Pancreatic Cancer, … First author DOI 10.1097/mpa.0000000000000878↗
  14. An important discovery on combination of irreversible electroporation and allogeneic natural killer cell immunotherapy for unresectable pancreatic cancer. Co-author DOI 10.18632/oncotarget.21974↗
  15. Alleviating visceral cancer pain in patients with pancreatic cancer using cryoablation and celiac plexus block. Co-author DOI 10.1016/j.cryobiol.2012.12.002↗
  16. Combination treatment with comprehensive cryoablation and immunotherapy in metastatic pancreatic cancer. Co-author DOI 10.1097/mpa.0b013e3182965dde↗
  17. Expression of CD44v6 and integrin-β1 for the prognosis evaluation of pancreatic cancer patients after cryosurgery. Co-author DOI 10.1186/1746-1596-8-146↗
  18. Cryosurgery for pancreatic cancer. First author DOI 10.3978/j.issn.2227-684x.2013.02.02↗
  19. Cryosurgery in combination with brachytherapy of iodine-125 seeds for pancreatic cancer. First author DOI 10.3978/j.issn.2227-684x.2013.04.04↗
  20. The establishment of the duplex real-time RT-PCR assay for the detection of CD44v6 in pancreatic cancer patients and clinical application. Co-author DOI 10.1002/bab.69↗
  21. Changes in the expression of serum markers CA242, CA199, CA125, CEA, TNF-α and TSGF after cryosurgery in pancreatic cancer patients. First author DOI 10.1007/s10529-012-0908-5↗
  22. Detection and clinical significance of CD44v6 and integrin-β1 in pancreatic cancer patients using a triplex real-time RT-PCR assay. Co-author DOI 10.1007/s12010-012-9752-2↗
  23. The efficacy evaluation of cryosurgery in pancreatic cancer patients with the expression of CD44v6, integrin-β1, CA199, and CEA. Co-author DOI 10.1007/s12033-011-9474-7↗
  24. [Percutaneous cryoablation and (125)I seed implantation combined with chemotherapy for advanced pancreatic cancer: report of 67 cases]. Co-author DOI 10.3760/cma.j.issn.0253-3766.2012.12.013↗

Closest collaborators

The 25 strongest of 35 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jibing Chen · 11 shared papers, 2013–2020 · strength 0.91
  2. Kecheng Xu · 14 shared papers, 2012–2018 · strength 0.79
  3. Mao Lin · 7 shared papers, 2017–2022 · strength 0.66
  4. Yangyang Ma · 4 shared papers, 2020–2023 · strength 0.61
  5. Mohammed Alnaggar · 4 shared papers, 2017–2020 · strength 0.36
  6. Lihua He · 6 shared papers, 2012–2017 · strength 0.24
  7. Chengli Li · 2 shared papers, 2021–2024 · strength 0.23
  8. Maoquan Li · 2 shared papers, 2021–2024 · strength 0.23
  9. Hongmei Li · 1 shared paper, 2023 · strength 0.18
  10. Shuying Li · 1 shared paper, 2023 · strength 0.18
  11. Gang Zhou · 5 shared papers, 2012–2013 · strength 0.18
  12. Zhongmin Wang · 1 shared paper, 2024 · strength 0.15
  13. Hongxin Niu · 1 shared paper, 2024 · strength 0.15
  14. Yuliang Li · 1 shared paper, 2024 · strength 0.15
  15. Baodong Gai · 1 shared paper, 2024 · strength 0.15
  16. Bin Liu · 1 shared paper, 2024 · strength 0.15
  17. Hong Zhao · 1 shared paper, 2024 · strength 0.15
  18. Fujun Zhang · 1 shared paper, 2024 · strength 0.15
  19. Kecheng Xu · 3 shared papers, 2012–2017 · strength 0.13
  20. Xiaoyan Zhang · 1 shared paper, 2020 · strength 0.11
  21. Yong Jiang · 1 shared paper, 2020 · strength 0.11
  22. Yingtian Wei · 1 shared paper, 2021 · strength 0.08
  23. Tianan Jiang · 1 shared paper, 2021 · strength 0.08
  24. Yinying Lu · 1 shared paper, 2021 · strength 0.08
  25. Liwei Wang · 1 shared paper, 2021 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.